Live feed14:05:04·985dNEWSReleasevia QuantisnowCymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: AnalystByQuantisnow·Wall Street's wire, on your screen.CBAYCymaBay Therapeutics Inc.GILDGilead Sciences Inc.ICPTIntercept Pharmaceuticals Inc.Health Care